Category Archives : News

Home  >>  News

EMBL: Celgene joins Open Targets

On May 15, 2018, Posted by , In News, With Comments Off on EMBL: Celgene joins Open Targets

May 2nd 2018 Celgene has joined Open Targets, the public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation Open Targets was founded in 2014 by EMBL-EBI, GSK and the Wellcome Sanger Institute The Open Targets Platform allows researchers to investigate causal links between…

DKFZ/HD Uni Hospital/EMBL: Genetic analysis for certain childhood brain tumors soon a standard-of-care?

On May 14, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ/HD Uni Hospital/EMBL: Genetic analysis for certain childhood brain tumors soon a standard-of-care?

An international team of researchers from the Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), the European Molecular Biology Laboratory (EMBL) and the German Cancer Consortium (DKTK) together with colleagues at the St. Jude Children’s Research Hospital in Memphis and the Hospital for Sick Children in Toronto has summarized…

DKFZ: High science distinction for Michael Baumann

On May 9, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: High science distinction for Michael Baumann

At its 100th Annual Meeting, the American Radium Society honored Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ), with the Janeway Gold Medal. The medal, which is awarded for outstanding contributions in cancer therapy, is one of the most prestigious distinctions in radiation oncology. Michael…

BioMed X and Merck extend research collaboration in oncology

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on BioMed X and Merck extend research collaboration in oncology

BioMed X announced the start of a new research project in collaboration with Merck at its Innovation Center in Heidelberg. The new team will focus on the identification of novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.     Dr. Jan Mauer, who joined the BioMed X…

EMBL – CRISPR: from clipping scissors to word processor

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on EMBL – CRISPR: from clipping scissors to word processor

Barcodes are used in a new way in the MAGESTIC platform, adding a new level of precision to CRISPR gene editing. Credit: Kelly Irvine/NIST Using the gene-editing tool CRISPR to snip at DNA is often akin to using scissors to edit a newspaper article. You can cut out words, but it’s…

Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

On May 4, 2018, Posted by , In News, By , , With Comments Off on Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the official launch of its Redirected Optimized Cell Killing (ROCK™) platform. Based on the company’s long-standing expertise in drug development and protein engineering, the ROCK™ platform enables the generation of both NK…

EMBL: Protein stability and solubility during cell cycle

On May 3, 2018, Posted by , In News, By , , With Comments Off on EMBL: Protein stability and solubility during cell cycle

  Dividing cell colored in a heat gradient, highlighting the variation in proteins’ thermal stability within and between different cell cycle stages. IMAGE: Aleksandra Krolik / EMBL EMBL scientists uncover large solubility and thermal stability changes of proteins during cell cycle The cell cycle is a highly dynamic process that…

University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

On May 2, 2018, Posted by , In News, By , , With Comments Off on University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

A novel vaccine candidate against the causative agent of malaria tropica, the most severe form of human malaria, has now been successfully tested for safety, tolerability and immunogenicity (ability to produce antibodies). Experts of the Department of Clinical Pharmacology and Pharmacoepidemiology of the University Hospital Heidelberg (directed by Prof. Dr….

European QuickFire Challenge for startups – Apply to receive €100,000 + @JLABS residency

On April 25, 2018, Posted by , In News, By , With Comments Off on European QuickFire Challenge for startups – Apply to receive €100,000 + @JLABS residency

European Innovation QuickFire Challenge! Innovators with ideas, technologies, and solutions that improve human healthcare and impact the European ecosystem can now apply for up to €100,000 in grants and one year of residency at an available JLABS location, including access to the global JLABS community. Encouraged applications from companies working…

DKFZ/Heidelberg University: ERC Advanced Grants for Hellmut Augustin and Christof Niehrs

On April 23, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ/Heidelberg University: ERC Advanced Grants for Hellmut Augustin and Christof Niehrs

The European Research Council ERC’s Advanced Grants promote visionary projects of fundamental research. This year, Hellmut Augustin (University of Heidelberg and DKFZ) and Christof Niehrs (University of Mainz and DKFZ) received the prestigious funding. Hellmut Augustin © DKFZ The European Research Council, set up in 2007, promotes fundamental research in…